Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

Published Date: 03 Jun 2025

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk

2.

Early Results for Anorexia Nervosa with Psilocybin.

3.

Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer

4.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

5.

A new device enhances liquid biopsy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot